Doxorubicin chemomyectomy in orbicularis oculi: Increasing drug infiltration at the injection site

Current Eye Research

Volumn 15, Issue 8, 1996, Pages 883-889

  McLoon, Linda Kirschen ^a   Wirtschafter, Jonathan D ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Blepharospasm; Eyelid; Facial muscles; Hemifacial spasm; Myotoxin; Rabbit

Indexed keywords

BUPIVACAINE; COLLAGENASE; DOXORUBICIN; HYALURONIDASE;

ANIMAL EXPERIMENT; ARTICLE; BLEPHAROSPASM; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISPOSITION; EYELID; FACE MUSCLE; HEMIFACIAL SPASM; INTRAMUSCULAR DRUG ADMINISTRATION; MUSCLE RESECTION; NONHUMAN; ORBICULARIS OCULI MUSCLE; PRIORITY JOURNAL; RABBIT; SKIN INJURY;

EID: 0029792346     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.3109/02713689609017630     Document Type: Article

References (20)

1. McLoon, L. K., Bauer, G. and Wirtschafter, J. (1991) Quantification of muscle loss in the doxorubicin treated orbicularis oculi of the monkey. Invest. Ophthal. Vis. Sci. 32, 1667-1673.
2. Wirtschafter, J. D. (1991) Clinical doxorubicin chemomyectomy. An experimental treatment for benign essential blepharospasm and hemifacial spasm. Ophthalmology, 98, 357-366.
3. Wirtschafter, J. D. (1994) Chemomyectomy of the orbicularis oculi muscles for the treatment of localized hemifacial spasm. J. Neuro-ophthal. 14, 199-204.
4. McLoon, L. K., Ekern, M. and Wirtschafter, J. D. (1992) Verapamil substantially increases the chemomyectomy effect of doxorubicin injected into rabbit or monkey eyelid. Invest. Ophthal. Vis. Sci. 33, 3228-3234.
5. McLoon, L. K., Wirtschafter, J. D. and Cameron, J. D. (1993) Muscle loss from doxorubicin injections into the eyelids of a patient with blepharospasm. Amer. J. Ophthal. 116, 646-648.
6. McLoon, L. K. and Wirtschafter, J. (1989) Doxorubicin chemomyectomy: injection of monkey orbicularis oculi results in selective muscle loss. Invest. Ophthal. Vis. Sci. 29, 1854-1859.
7. McLoon, L. K., Luo, X. X. and Wirtschafter, J. (1993) Acute morphologic changes in orbicularis oculi muscle after doxorubicin injection into the eyelid. Muscle Nerve, 16, 737-743.
8. Bellamy, W. T., Dorr, R. T., Dalton, W. S. and Alberts, D. S. (1988) Direction relation of DNA lesions in multidrug resistant human myeloma cells to intracellular doxorubicin concentration. Cancer Res. 48, 6360-6364.
9. Hindenberg, A. A., Gervasoni, J., Drishna, S., Stewart, V., Rosado, M., Lutzky, J., Bhalla, K., Baker, M. and Taub, R. N. (1989) Intracellular distribution and pharmacokinetics of daunorubicin in anthracycline-sensitive and -resistant HL-60 cells. Cancer Res. 49, 4607-4614.
10. Lander, T., McLoon, L. K. and Wirtschafter, J. D. (1996) Orbicularis oculi muscle fibers are relatively short and heterogeneous in length. Invest. Ophthal. Vis. Sci. 37. In Press.
11. Wirtschafter, J. D., Lander, T., Baker, R., Stevanovic, M., Kirsch, J. and McLoon, L. K. (1994) Heterogeneous length and in-series arrangement of orbicularis oculi muscle: individual myofibers do not extend the length of the eyelid. Trans. Amer. Ophthal. Soc. 92, 71-90.
12. Benoit, P. W. and Belt, W. D. (1970) Destruction and regeneration of skeletal muscle after treatment with a local anesthetic, bupivacaine. J. Anat. 107, 547-556.
13. Hall-Craggs, E. C. B. (1975) Rapid degeneration and regeneration of a whole skeletal muscle following treatment with bupivacaine (Marcain). Exp. Neurol. 43, 349-358.
14. McLoon, L. K. and Wirtschafter, J. D. (1993) Regional differences in the subacute response of rabbit orbicularis oculi to bupivacaine-induced myotoxicity as quantified with a neural cell adhesion molecule immunohistochemical marker. Invest. Ophthal. Vis. Sci. 34, 3450-3458.
15. Brooke, M. H. and Kaiser, K. K. (1970) Muscle fiber types: how many and what kind? Arch. Neurol. 23, 369-379.
16. McLoon, L. K. and Wirtschafter, J. (1991) Regional differences in the orbicularis oculi muscle: conservation between species. J. Neurol. Sci. 104, 197-202.
17. Doroshow, J. H., Tallent, C. and Schechter, J. E. (1985) Ultrastructural features of Adriamycin-induced skeletal and cardiac muscle toxicity. Amer. J. Pathol. 118, 288-297.
18. Beckenlehner, K., Bannke, S., Spruss, T., Bernhardt, G., Schoenenberger, H. and Schiess, W. (1992) Hyaluronidase enhances the activity of Adriamycin in breast cancer models in vitro and in vivo. J. Cancer Res. Clin. Oncol. 118, 591-596.
19. McLoon, L. K., Ozel, B., and Wirtschafter, J. D. (1995) Cyclosporin protects the eyelid skin from injury after injection of doxorubicin. Invest. Ophthal. Vis. Sci. 36, 1433-1440.
20. McLoon, L. K. and Wirtschafter, J. D. (1996) Corticotropin releasing factor dramatically reduces inflammation at the site of local doxorubicin chemomyectomy. (Abstract). Invest. Ophthal. Vis. Sci. 37 (Suppl.), S615.